JNX0 Stock Chart & Stats
€0.01
<€0.01(46.15%)
At close: 4:00 PM EDT
€0.01
<€0.01(46.15%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)228.00
Market Cap
€1.90M
Enterprise Value€3.38
Total Cash (Recent Filing)€25.13K
Total Debt (Recent Filing)€40.00K
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding61,246,628
10 Day Avg. Volume0
30 Day Avg. Volume228
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.51
Price to Sales (P/S)48.92
P/FCF Ratio-26.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp revenue rebound indicates improving product demand or commercial execution. Sustaining this growth could expand operating leverage and provide a larger base from which the company can pursue breakeven.
Improved Gross MarginA positive gross margin suggests better pricing, product mix, or cost control at the gross-profit level. If maintained as sales scale, this improvement can support stronger contribution economics and reduce the path to profitability.
Low Debt BurdenLow absolute debt limits interest obligations and refinancing exposure, preserving some flexibility while the company develops its products. This is a relative strength, although it does not eliminate the need for additional funding.
Bears Say
Persistent Net LossesThe large loss relative to the current revenue base shows that operating costs remain far above the company’s commercial scale. Continued losses could delay self-sufficiency and increase dependence on external capital or restructuring.
Negative Shareholders’ EquityNegative equity reflects accumulated losses and a weakened capital base, limiting financial flexibility. It may constrain the company’s ability to absorb setbacks, support operations internally, or secure financing on favorable terms.
Ongoing Cash ConsumptionNegative operating and free cash flow means the business is not yet funding itself through operations. Although cash burn has narrowed, sustained deficits keep liquidity and future financing needs as material execution risks.
Therma Bright News
JNX0 FAQ
What was Therma Bright’s price range in the past 12 months?
Therma Bright lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Therma Bright’s market cap?
Therma Bright’s market cap is €1.90M.
When is Therma Bright’s upcoming earnings report date?
Therma Bright’s upcoming earnings report date is Dec 01, 2026 which is in 80 days.
How were Therma Bright’s earnings last quarter?
Therma Bright released its earnings results on Jun 25, 2026. The company reported -€0.002 earnings per share for the quarter.
Is Therma Bright overvalued?
According to Wall Street analysts Therma Bright’s price is currently Overvalued.
Does Therma Bright pay dividends?
Therma Bright does not currently pay dividends.
What is Therma Bright’s EPS estimate?
Therma Bright’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Therma Bright have?
Therma Bright has 61,246,628 shares outstanding.
What happened to Therma Bright’s price movement after its last earnings report?
Therma Bright reported an EPS of -€0.002 in its last earnings report. Following the earnings report the stock price went up 23.077%.
Which hedge fund is a major shareholder of Therma Bright?
Currently, no hedge funds are holding shares in DE:JNX0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Therma Bright
Established in Toronto, Canada, in 2001 as The Jenex Corporation before rebranding to Therma Bright Inc. in February 2018, Therma Bright Inc. specializes in creating and distributing various medical and consumer health products. Their diverse offerings include rapid COVID-19 diagnostic tests like AcuVid, which screens for both antigens and antibodies. For pain relief, they provide devices such as Benepod, a hot and cold contrast therapy system designed to manage discomfort without medication. The company also addresses circulatory issues with Venowave, a medical compression pump aimed at mitigating symptoms associated with poor circulation. Furthermore, Therma Bright caters to the cosmeceutical industry with products like InterceptCS, a cold sore prevention system utilizing safe, controlled topical heat, and TherOZap, a thermal device that alleviates the pain, itching, and inflammation from insect bites and stings by reducing the inflammatory response. Their clientele spans both individual consumers and healthcare practitioners.
Technical Analysis
―
Perimeter Medical Imaging AI
―
Profound Medical
―
Theralase Technologies
―
Aquarius Surgical Technologies
―